Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Reporting of 6-month vs 12-month data in a clinical trial of celecoxib.

Hrachovec JB, Mora M.

JAMA. 2001 Nov 21;286(19):2398; author reply 2399-400. No abstract available.

PMID:
11712924
2.

Arthritis. Should you be taking a COX-2 inhibitor?

[No authors listed]

Harv Health Lett. 2001 Nov;27(1):1-3. Review. No abstract available.

PMID:
11724695
3.

COX-2 inhibitors: the next generation of non-steroidal anti-inflammatory drugs.

Schachna L, Ryan PF.

Med J Aust. 1999 Aug 16;171(4):175-6. Review. No abstract available.

PMID:
10494231
4.

[COX-2 specific inhibitors: are NSAIDs and the stomach become reconcilied?].

Bannwarth B.

Gastroenterol Clin Biol. 2001 Apr;25(4 Suppl):B79-84. Review. French. No abstract available.

5.

Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs.

Perazella MA, Tray K.

Am J Med. 2001 Jul;111(1):64-7. Review. No abstract available.

PMID:
11448662
6.

[Specific inhibitors of cyclooxygenase type 2] ].

Tomasová-Studýnková J.

Vnitr Lek. 2002 May;48(5):403-8. Review. Czech.

PMID:
12061207
7.

[Therapy with preferential and specific COX-2 inhibitors].

Stichtenoth DO, Frölich JC.

Internist (Berl). 2001 Mar;42(3):421-6. Review. German. No abstract available.

8.

COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.

Ray WA, MacDonald TM, Solomon DH, Graham DJ, Avorn J.

Pharmacoepidemiol Drug Saf. 2003 Jan-Feb;12(1):67-70. Review. No abstract available.

PMID:
12616850
9.

Cyclooxygenase inhibition: between the devil and the deep blue sea.

Hawkey CJ.

Gut. 2002 May;50 Suppl 3:III25-30. Review.

10.

New NSAIDs and gastroduodenal damage.

Folco GC.

Ital J Gastroenterol. 1996 Dec;28 Suppl 4:28-9. Review.

PMID:
9032579
11.

[Neutrophil-endothelium interaction].

Tsuji S, Kawano S.

Nihon Rinsho. 2002 Feb;60 Suppl 2:201-6. Review. Japanese. No abstract available.

PMID:
11979778
12.

COX-2 inhibitors: no pain, no heart gain?

[No authors listed]

Harv Heart Lett. 2001 Dec;12(4):2-4. Review. No abstract available.

PMID:
11751079
13.

The coxibs, selective inhibitors of cyclooxygenase-2.

FitzGerald GA, Patrono C.

N Engl J Med. 2001 Aug 9;345(6):433-42. Review. No abstract available.

PMID:
11496855
14.

Is there a place for non-selective NSAIDs in the treatment of arthritis?

Crofford LJ.

Joint Bone Spine. 2002 Jan;69(1):4-7. Review. No abstract available.

PMID:
11858355
15.

Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.

Patrono C, Patrignani P, García Rodríguez LA.

J Clin Invest. 2001 Jul;108(1):7-13. Review. No abstract available.

16.

[New anti-inflammatory analgetics--are they needed?].

Paakkari I.

Duodecim. 1999;115(20):2217-24. Review. Finnish. No abstract available.

PMID:
11973925
17.

The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.

Spiegel BM, Targownik L, Dulai GS, Gralnek IM.

Ann Intern Med. 2003 May 20;138(10):795-806. Review.

PMID:
12755551
18.

[Current post-marketing information. Effects and adverse effects of celecoxib].

Schmidt H, Geisslinger G.

Pharm Unserer Zeit. 2002;31(2):180-7. Review. German. No abstract available.

PMID:
11977454
20.

Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.

Moore PA, Hersh EV.

J Am Dent Assoc. 2001 Apr;132(4):451-6. Review.

PMID:
11315375

Supplemental Content

Support Center